We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-13.22%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.03B
AUM Growth
+$135M
(+7.1%)
Cap. Flow
+$465M
Cap. Flow
% of AUM
22.9%
Top 10 Holdings %
Top 10 Hldgs %
63.8%
Holding
57
New
6
Increased
19
Reduced
9
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$187M |
| 2 |
Steris
STE
|
+$105M |
| 3 |
Corcept Therapeutics
CORT
|
+$55M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
+$36.8M |
| 5 |
Cable One
CABO
|
+$36.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$29.9M |
| 2 |
Apple
AAPL
|
+$22.6M |
| 3 |
Inogen
INGN
|
+$16.2M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$13.9M |
| 5 |
Nkarta
NKTX
|
+$8.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.54% |
| 2 | Technology | 15.07% |
| 3 | Financials | 6.4% |
| 4 | Communication Services | 2.82% |
| 5 | Consumer Discretionary | 2.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$656B
| $288M | 14.17% |
1,525,550
| – | – |
|
|
CTLT
2
DELISTED
CATALENT, INC.
CTLT
| $175M | 8.63% |
1,632,878
+361,171
| +28% | +$36.8M |
|
|
3
Stryker
SYK
$133B
| $159M | 7.81% |
+796,941
| New | +$187M |
|
4
Boston Scientific
BSX
$68.5B
| $131M | 6.44% |
3,508,788
+45,211
| +1% | +$1.84M |
|
5
Brookfield
BN
$104B
| $130M | 6.4% |
5,420,233
| – | – |
|
6
ASML
ASML
$608B
| $102M | 5.04% |
215,000
-99
| -0% | -$55.3K |
|
|
7
Steris
STE
$22.4B
| $96.4M | 4.75% |
+467,687
| New | +$105M |
|
8
Salesforce
CRM
$149B
| $79M | 3.89% |
478,500
+179,500
| +60% | +$31.7M |
|
|
ACLX
9
DELISTED
Arcellx
ACLX
| $72.6M | 3.58% |
4,016,878
| – | – |
|
|
10
Apple
AAPL
$4.99T
| $63.1M | 3.11% |
461,379
-149,500
| -24% | -$22.6M |
|
|
11
Corcept Therapeutics
CORT
$10.1B
| $60.1M | 2.96% |
+2,526,490
| New | +$55M |
|
12
TSMC
TSM
$2.03T
| $58.1M | 2.86% |
710,780
+252,000
| +55% | +$23.3M |
|
|
13
Cable One
CABO
$249M
| $57.3M | 2.82% |
44,473
+28,600
| +180% | +$36.4M |
|
14
Alibaba
BABA
$276B
| $56.9M | 2.8% |
500,827
| – | – |
|
15
Edgewise Therapeutics
EWTX
$4.34B
| $44.5M | 2.19% |
5,587,207
| – | – |
|
16
Mirum Pharmaceuticals
MIRM
$6.84B
| $37.9M | 1.87% |
2,027,324
-172,676
| -8% | -$4.07M |
|
|
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
| $28.3M | 1.39% |
2,635,000
+74,789
| +3% | +$616K |
|
|
18
Nkarta
NKTX
$159M
| $26.9M | 1.32% |
2,180,000
-613,863
| -22% | -$8.06M |
|
19
BioMarin Pharmaceuticals
BMRN
$12B
| $26.3M | 1.3% |
+317,500
| New | +$25.3M |
|
|
VECT
20
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $18M | 0.89% |
3,339,484
-40,918
| -1% | -$220K |
|
21
Vaxcyte
PCVX
$7.88B
| $17.9M | 0.88% |
+823,705
| New | +$19.1M |
|
|
BPMC
22
DELISTED
Blueprint Medicines
BPMC
| $16M | 0.79% |
316,674
+89,148
| +39% | +$5.22M |
|
23
Milestone Pharmaceuticals
MIST
$133M
| $15.6M | 0.77% |
2,530,003
| – | – |
|
|
IOBT
24
DELISTED
IO Biotech
IOBT
| $15.3M | 0.75% |
3,277,932
| – | – |
|
25
Insmed
INSM
$22.6B
| $15.2M | 0.75% |
770,000
+64,162
| +9% | +$1.34M |
|
Similar funds
HCA
GX
MP
FLII
CA
IC
WTA
CCA
Novo Holdings A/S's Q2 2022 Portfolio in Review
As of Q2 2022, Novo Holdings A/S held 57 positions worth $2.03B, up 7.1% from $1.9B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Novo Holdings A/S deployed $465M of net new capital in Q2 2022, opening 6 new positions and adding to 19 existing holdings. Its largest new stake was Stryker: 796,941 shares worth $159M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 49% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $29.9M trimmed.
- Novo Holdings A/S's largest Q2 2022 buy was Stryker: 796,941 shares worth $159M.
- Novo Holdings A/S added most to CATALENT, INC. in Q2 2022, an estimated $36.8M increase.
- Novo Holdings A/S's biggest Q2 2022 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $29.9M.
- Novo Holdings A/S fully exited Iovance Biotherapeutics in Q2 2022, selling an estimated $13.9M.
- Novo Holdings A/S's ten largest holdings make up 64% of its $2.03B portfolio in Q2 2022.
- Novo Holdings A/S opened 6 new positions and closed 3 in Q2 2022.
- Novo Holdings A/S's portfolio value rose 7.1% quarter-over-quarter to $2.03B.
Based on Novo Holdings A/S's 13F filing for Q2 2022, filed 15 Aug 2022.